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Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) mediates the adherence of P. falciparum-
infected erythrocytes to placental syncytiotrophoblasts via interactions with chondroitin sulfate A (CSA), a
characteristic of pregnancy-associated malaria. Pregnancy-associated malaria predicts increased susceptibility
of newborns to malaria, and it is postulated that transplacental passage of parasite antigen induces immune
regulatory activity in the neonate. We wished to examine the immune responsiveness to a CSA-binding domain
of PfEMP1, the DBL-3 domain, in cord and maternal venous blood obtained from pregnancies with various
histories of P. falciparum infection. We assessed in vitro T-cell cytokine and plasma immunoglobulin G (IgG)
and IgM responses to four peptides corresponding to highly conserved regions of a DBL-3 domain common
to central African parasite isolates. The presence of placental P. falciparum infection at delivery was associated
with elevated frequencies of DBL-3 peptide-specific CD3 interleukin-10-positive T cells in cord blood, while
treatment and clearance of infection prior to delivery was associated with elevated frequencies of CD3 gamma
interferon-positive T cells. DBL-3 peptide-specific IgM antibodies were detected in 12 of 60 (20%) cord
plasma samples from those born to mothers with P. falciparum infection during pregnancy. Consistent with
polyclonal anti-PfEMP1 antibody responses that are associated with protection against pregnancy-associated
malaria, the presence of maternal IgG antibodies with specificity for one of the DBL-3 peptides showed a
parity-dependent profile. These data demonstrate that peptides corresponding to conserved regions of the
DBL-3 domain of PfEMP1 are immunogenic in P. falciparum-infected mothers and their offspring.
In malaria-endemic regions, pregnancy is associated with
increased risk of Plasmodium falciparum infection that has
deleterious consequences for both maternal and neonatal
health (32). Susceptibility to pregnancy-associated malaria is
related to the abundant expression of chondroitin sulfate A
(CSA) on placental syncytiotrophoblasts. Chondroitin sulfate
A is a proteoglycan that acts as a receptor for P. falciparum
erythrocyte membrane protein 1 (PfEMP1) (24) expressed on
the surface of infected erythrocytes (26). Infected erythrocytes
accumulate in the intervillous spaces of the placenta (8), and
naturally acquired antibodies that interfere with CSA-medi-
ated adherence of infected erythrocytes are associated with
protection against pregnancy-associated malaria (9) and in-
crease with parity (25).
Variants of PfEMP1 are encoded by individual members of
the var multigene family and most comprise at least one cys-
teine-rich interdomain region with a variable number of Duffy
binding-like (DBL) domains (29). The repertoire of PfEMP1
variants expressed on infected erythrocytes found in associa-
tion with pregnancy-associated malaria is narrower than that
expressed on infected erythrocytes of non-pregnancy-associ-
ated malaria parasites, perhaps due to constraints imposed by
receptor specificity, which may help to explain the relatively
rapid acquisition of immunity to pregnancy-associated malaria
(12). The DBL-3 domain of PfEMP1 expressed by placental
parasite isolates binds to CSA (4, 10), and antibodies directed
against recombinant DBL-3 block infected erythrocyte adhe-
sion to CSA (5). Monoclonal antibodies raised against DBL-3
bind to the surface of CSA-adhering parasites obtained from
different geographic areas (19), which is itself probably a re-
flection of the relatively conserved nature of the DBL-3 do-
main that supports the feasibility of a vaccine against pregnan-
cy-associated malaria.
The knowledge of B- and T-cell activity directed to specific
epitopes of PfEMP1 in naturally exposed humans is very lim-
ited (1), and no studies have reported PfEMP1-specific im-
mune responses in the cord blood from neonates born to
mothers with malaria. Epidemiological studies suggest that
pregnancy-associated malaria increases the likelihood of early
infection in the newborn (6, 18), possibly as a result of antigen
exposure inducing immunosuppressive pathways during fetal
development (2, 3). In this study, we wished to determine
whether DBL-3 domain-specific antibody and T-cell re-
sponses are present in cord blood and maternal venous blood.
We tested a panel of peptides corresponding to conserved
regions of the DBL-3 domain present in closely related
PfEMP1 variants expressed by placental parasites isolated
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from Cameroon and Gabon (15, 16). For comparative pur-
poses, we also used recombinant glutamate-rich protein, a P.
falciparum antigen shown to be present in cord blood (14).
DBL-3 domain sequence-specific peptide selection was based
both on amino acid conservation and HLA-DR allele-binding
agretope prediction (23). Our results show that maternal P.
falciparum infection during pregnancy is associated with in-
creased frequencies of DBL-3 peptide-specific T cells and
IgM in cord blood.
MATERIALS AND METHODS
Study population. The study was carried out at the Albert Schweitzer Hospital
in Lambare´ne´, Gabon, a site with perennial transmission of P. falciparum (33).
Informed consent for participation was obtained from mothers prior to inclusion
in the study. From May to December 2003, 85 maternal venous and umbilical
cord blood samples were collected into heparinized Vacutainer tubes (BD Bio-
sciences, Heidelberg, Germany). The presence of P. falciparum parasites in the
maternal peripheral, placental, and cord blood at the time of delivery was
determined through microscopic examination of Giemsa-stained thick and thin
smears. The medical records of uninfected mothers were examined to verify
those who had been appropriately diagnosed and treated for P. falciparum
malaria episodes during their pregnancy. The majority of those with such a
history received chemotherapy with quinine, a drug with 100% efficacy for the
treatment of uncomplicated P. falciparum malaria in the study area (22), at least
2 weeks prior to delivery.
Based on these criteria the following distinct groups were defined: (i) negative:
no evidence of P. falciparum parasites or active infection in any compartment at
delivery and no record of malaria during pregnancy; (ii) placenta positive: P.
falciparum asexual stage parasites present in placental blood; and (iii) treated: no
evidence of P. falciparum parasites or active infection in any compartment at
delivery but recorded history of a diagnosed and treated malaria episode during
pregnancy. A significantly higher proportion of primiparous mothers had pla-
cental P. falciparum infection compared with those who were multiparous (P 
0.001). Ethical clearance for the study was given by the ethics committee of the
International Foundation of the Albert Schweitzer Hospital in Lambare´ne´.
Isolation of mononuclear cells and cell culture. Cord blood mononuclear cells
were isolated by standard density-gradient centrifugation on Ficoll-Paque (Am-
ersham, Freiburg, Germany). Freshly isolated cells were resuspended at 5  106
cells/ml in complete medium comprising RPMI 1640 medium (Sigma, Diesen-
hofen, Germany) supplemented with 10% (wt/vol) human serum (AB) (Sigma),
1 mM L-alanylglutamine (Life Technologies, Grand Island, NY), 100 U/ml pen-
icillin, 100 g/ml streptomycin (Life Technologies), and 1 mM sodium pyruvate
(Life Technologies). To facilitate costimulation 0.5 g/ml of both anti-human
CD28 and CD49d antibodies were added (BD Biosciences, San Jose, CA) (11).
A total of 0.6 ml of cell suspension was placed in a 48-well flat-bottomed tissue
culture plate (Falcon). Peptides (10 g/ml), purified protein derivative of Myco-
bacterium tuberculosis (10 g/ml) (StatensSerumInstitut, Copenhagen, Den-
mark), or phytohemagglutinin (5 g/ml) (Sigma, Diesenhofen, Germany) was
added to the cells followed by incubation at 37°C in a humidified 5% CO2
atmosphere. For intracellular cytokine analysis, 10 g/ml brefeldin A (Sigma)
was added after 18 h of culture and the cells were incubated for a further 4 hours
prior to fixation and antibody staining.
Measurement of intracellular cytokine production by flow cytometry analysis.
For the analysis of intracellular cytokines and surface markers cells were washed
twice in cold phosphate-buffered saline (PBS) immediately after culture, fixed
with 2% paraformaldehyde/PBS, and stored at 4°C. For staining with fluores-
cently labeled antibodies cells were washed in PBS and incubated on ice for 15
min with PBS-10% fetal bovine serum containing 2 l of Fc receptor blocking
reagent (Miltenyi Biotec, Bergisch Gladbach, Germany), followed by surface-
staining antibody specific for human CD3 (SK7) (conjugated to peridinin chlo-
rophyll protein) or isotype control antibody mouse IgG1-peridinin chlorophyll
protein (MOPC-31C). For intracellular staining of gamma interferon (IFN-),
interleukin-10 (IL-10), and IL-13, Cytofix/Cytoperm Plus kits (BD Biosciences,
Heidelberg, Germany) were used according to the manufacturer’s protocol using
antibodies IFN--fluorescein isothiocyanate (B27), IL-10-allophycocyanin
(JES3-19F1), IL-13-phycoerythrin (JES10-5A2) or isotype control antibodies
mouse IgG1-fluorescein isothiocyanate (MOPC-21), rat IgG2a-allophycocyanin
(R35-95), and rat IgG1-phycoerythrin (A11-01). Flow cytometry was performed
on a FACScan flow cytometer with CellQuest (version 3.3) data analysis software
(BD Biosciences). A minimum of 100,000 lymphocytes were analyzed. The re-
sponses measured from seven malaria-unexposed Europeans were used to de-
termine the cutoff value for a positive response in the study subjects (mean of net
response  3 standard deviations).
Detection of cord blood and maternal venous blood IgM and IgG antibodies
specific for DBL-3 peptides, glutamate-rich protein, and purified protein de-
rivative by ELISA. The antibody responses to the four DBL-3 peptides, gluta-
mate-rich protein (gift from Michael Theisen) (34), and purified protein deriv-
ative of Mycobacterium tuberculosis (StatensSerumInstitut, Copenhagen,
Denmark) were determined by a standard enzyme-linked immunosorbent assay
(ELISA). Briefly, the wells of flat-bottomed microtiter plates (Immulon2; Dy-
natech) were coated either with 100 l (10 g/ml) of individual DBL-3 pep-
tides, 100 l (100 ng/ml) of glutamate-rich protein, or 100 l (100 ng/ml) of
purified protein derivative, all diluted in PBS (0.01 M, pH 7.2). After overnight
incubation at 4°C, the plates were washed twice with PBS containing 0.05%
Tween 20 (PBS-T) and blocked with PBS-T containing 2% bovine serum albu-
min (PBS-TB). Plasma samples diluted at 1:200 in PBS-TB were added in
duplicate wells and allowed to react for 2 hours at room temperature. Unbound
antibodies were removed by washing the plates four times with PBS-T. Peroxi-
dase-conjugated goat anti-human IgG or IgM antibody (Biosource, Solingen,
Germany) at a dilution of 1:50,000 in PBS-TB was added. After 1 hour, plates
were washed four times with PBS-T, and 100 l/well of TMB (tetramethylben-
zidine) substrate (Biosource) was added. The reaction was stopped after 10 min
by the addition of 100 l of 1.8 N H2SO4 and the absorbance was read at 450 nm.
In order to calculate the relative antibody concentrations of the test plasma
samples, standard curves using serial dilutions of pooled plasma samples from
five Gabonese adults who tested positive for DBL-3-specific antibodies were
generated. In order to determine the cutoff value for a positive result, we
calculated the mean optical density plus three standard deviations of plasma
samples from negative controls (10 Europeans with no known exposure to P.
falciparum).
Peptides. Synthetic peptides corresponded to a DBL-3 sequence from a
placentally derived P. falciparum isolate obtained in Cameroon in 1996 (isolate
732, GenBank accession number AF334807) (16) that showed 98% amino acid
sequence identity to two isolates obtained in Lambare´ne´, Gabon in 2000 (15).
The SYFPEITHI algorithm (23) was used to predict motifs most likely to bind to
HLA-DR molecules present in the Gabonese population (21), and belonging to
the main HLA-DR super type (30). Figure 1 shows the amino acid sequences
with the algorithm scores of the four peptides used in this study. The DBL-3
peptides were synthesized at 98% purity by ThermoHybaid (Ulm, Germany),
and resuspended in sterile PBS.
Statistical analyses. All figures were drawn using StatView. The significance of
differences in continuous variables between groups was assessed using the non-
parametric Kruskal-Wallis test and the Mann-Whitney U test (two groups), for
associations between two continuous variables the nonparametric Spearman
rank correlation test, and for differences in proportions the Fisher exact test.
RESULTS
In vitro T-cell cytokine responses to DBL-3 peptides in
cord and maternal blood. Flow cytometric analysis was used to
measure intracellular IFN-, IL-13, and IL-10 in CD3 cells
after overnight stimulation with the four DBL-3 peptides of
cord blood mononuclear cells, maternal peripheral blood
mononuclear cells, and malaria-unexposed European periph-
eral blood mononuclear cells. The proportion of cord blood
mononuclear cell samples that produced cytokine in response
to peptide stimulation ranged from 0.09 to 0.23, with DBL120
inducing the greatest response (Fig. 2A), while the proportion
of maternal peripheral blood mononuclear cell samples with
positive responses ranged from 0.19 to 0.29 (Fig. 2A). Cord
blood mononuclear cells samples from the treated group of
neonates contained significantly higher percentages of DBL-3
peptide-specific CD3IFN- cells compared to the negative
group, while cord blood mononuclear cells samples from the
placenta-positive group contained significantly higher percent-
ages of DBL-3 peptide-specific CD3IL-10 cells (Fig. 2B).
Cord blood mononuclear cells samples from both the pla-
centa-positive and treated groups of neonates contained ele-
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vated numbers of CD3IL-13 cells compared to negative
neonates, though the differences were not statistically signifi-
cant. The percentages of DBL-3 peptide-specific CD3 cells
displaying either IFN-, IL-13, or IL-10 activity were statisti-
cally similar among cocultures from the three groups of moth-
ers, though there were trends toward higher percentages of
CD3IL-13 cells in the negative group, and of CD3IFN-
and CD3IL-10 cells in the placenta-positive group (Fig. 2B).
Strong associations between maternal DBL-3 peptide-specific
cytokine activity and parity were not observed (data not
shown). Comparison of the cytokine activity of cord and ma-
ternal CD3 cells following nonspecific stimulation with phy-
tohemagglutinin showed no significant differences between the
groups segregated according to maternal P. falciparum infec-
tion status (Fig. 2C).
IgM and IgG antibodies with specificity for DBL-3 pep-
tides are present in cord and maternal plasma. Plasma sam-
ples collected from cord blood and maternal venous blood
were analyzed for IgM and IgG antibodies with specificity for
the four DBL-3 peptides, and for comparative purposes re-
combinant glutamate-rich protein and purified protein deriva-
tive protein preparations. Maternally derived IgM antibodies
do not cross the placental barrier and P. falciparum-specific
IgM detected in cord plasma is therefore assumed to reflect
stimulation of fetal B cells by transplacentally transferred an-
tigen. With the exception of DBL78, the highest proportions of
cord blood samples that contained IgM antibodies specific for
the DBL-3 peptides or glutamate-rich protein were found in
the placenta-positive group (Fig. 3A).
The proportions of positive responses for each peptide
among all neonates were DBL25 (8%), DBL78 (8%), DBL120
(10%) and DBL132 (4%). One-third of cord plasma samples
with IgM specific for DBL120 contained IgM antibodies spe-
cific for DBL132. In the treated group of neonates, the pro-
portions of plasma samples with IgM responses to DBL25,
DBL78, DBL120, and glutamate-rich protein were more than
1.5-fold higher than found in plasma of the negative group
(Fig. 3A). Overall, IgM with specificity for any DBL-3 peptide
was detected in 7 of 32 (22%) cord plasma samples from
neonates born to mothers with placental P. falciparum infec-
tion at delivery, and 5 of 28 (18%) cord samples from neonates
whose mothers were treated for P. falciparum infection during
pregnancy, compared with only 1 of 25 (4%) cord samples
from neonates whose mothers did not have P. falciparum in-
fection during pregnancy (Fig. 3B).
The mean  3 standard deviations of IgM antibody levels
detected in plasma samples of malaria-naı¨ve (unexposed) Eu-
ropeans was used to establish the cutoff value for a positive
response (illustrated for DBL120-specific IgM in Fig. 3C). The
proportion of mothers’ plasma samples from all groups with
IgM specific for at least one peptide was 77 of 85 (90%). No
correlations were observed between cord and maternal IgM
antibody levels for any of the DBL-3 peptides, or for gluta-
mate-rich protein or purified protein derivative (data not
shown). There was a strong positive correlation (  0.72, P 
0.001) between cord and maternal venous blood DBL-3 pep-
tide-specific IgG antibody levels that was not affected by ma-
ternal infection history at the time of delivery (Fig. 3D).
Compared with plasma from negative mothers, plasma from
placenta-positive mothers contained significantly higher levels
of IgG antibodies with specificity for DBL120 (P  0.009) and
of IgM antibodies with specificity for DBL25, DBL78, and
glutamate-rich protein (P  0.030, 0.002, and 0.007, respec-
tively) (Fig. 4A and B). Treatment for malaria during preg-
nancy was not associated with significantly different DBL-3
peptide-specific IgG and IgM antibody levels compared to the
levels observed in negative mothers (Fig. 4A and B).
We found a positive association between parity and levels of
IgG antibodies in the plasma of negative mothers with speci-
ficity for either DBL78 or DBL120, and levels of IgM antibod-
ies specific for DBL120 (  0.47 and P  0.050;   0.51 and
P  0.043; and   0.47, and P  0.038, respectively) (Fig. 5A
and B). No such relationships were found between parity and
the levels of either glutamate-rich protein- or purified protein
derivative-specific IgG or IgM antibodies (Fig. 5).
FIG. 1. A) Amino acid sequences of peptides corresponding to
conserved regions of DBL-3, and B) their SYFPEITHI score for
HLA-DR phenotypes.
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DISCUSSION
This study had as its foundation the evidence-based premise
that conserved regions of a domain of a P. falciparum protein
antigen implicated in parasite persistence during pregnancy
would be immunogenic, and furthermore, that the presence of
antigen in the placental compartment could lead to transpla-
cental transfer and in utero sensitization of the fetal immune
system. Thus, we selected four peptides from conserved re-
gions of the PfEMP1 CSA-binding domain, DBL-3, which
displays a very high degree of spatial and temporal conserva-
tion within Central African P. falciparum placental isolates (15,
16). This level of conservation in PfEMP1 suggests that these
regions may be fundamental to the parasite’s survival in the
placental compartment, perhaps via participation in CSA bind-
ing. B-cell epitopes that also bind CSA have been identified in
other DBL-3 domain variants, and a CSA-binding PfEMP1
variant associated with pregnancy-associated malaria that con-
tains no DBL-3 domain has been described (10, 27, 28). The
latter findings clearly imply the existence of a degree of diver-
sity in the receptor-ligand interactions that are thought to be
integral to the development and persistence of pregnancy-
associated malaria.
The algorithm-based method we used to identify potential
agretopes, and by extension T-cell epitopes, within the DBL-3
domain revealed peptides that are recognized by both B and T
cells from the mother and fetus. We found that antibody re-
sponses with specificity for at least one of the peptides
(DBL120) were significantly enhanced in the peripheral blood
of mothers with pregnancy-associated malaria, and that they
showed the pattern of parity-dependence commonly associated
FIG. 2. Intracellular cytokine activity of cord and maternal T cells following stimulation of cord blood mononuclear cells and peripheral blood
mononuclear cells with DBL-3 peptides. A) Percentage of samples containing CD3 cells with a cytokine response to DBL-3 peptides in cord
and maternal blood. The mean net percent gated CD3 cells in cord and maternal blood that produce IFN- , IL-13, or IL-10 in response to B)
DBL-3 peptides or C) phytohemagglutinin (PHA) in groups segregated by maternal P. falciparum infection history during pregnancy. Bar graphs
illustrate mean percentages with standard deviations. Sample sizes: European control, 7; Cords: negative, 19; placenta positive, 14; treated, 17;
Mothers: negative, 8; placenta positive, 7; treated, 7. *, P  0.05 by either Fisher exact test or the nonparametric Mann-Whitney test.
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with protection against pregnancy-associated malaria (25, 31).
In the same context it is noteworthy that similar although
mostly statistically nonsignificant patterns were observed for
the antibody responses to the DBL78 peptide, which was pre-
dicted to bind most strongly to HLA-DRB1*1501, which is a
particularly common allele among the Gabonese.
We interpret the presence of DBL-3 peptide- as well as
glutamate-rich protein-specific IgM in cord blood plasma sam-
ples primarily of those born to mothers with past or present P.
falciparum infection as confirmation of our premise concerning
in utero sensitization. The proportions of cord samples we
found with IgM specific for DBL-3 peptides (4 to 10%) are
comparable to the proportion of Kenyan cord samples con-
taining IgM antibodies specific for recombinant P. falciparum
MSP-119 (6%) (17), and to the proportion of Cameroonian
cord samples with IgM specific for crude parasite lysate prep-
arations (14%) (36). These findings, coupled with our obser-
vation of DBL-3 peptide-specific cytokine activity, identify
PfEMP1, or at least components thereof, as a parasite antigen
that is transferred transplacentally and that sensitizes fetal T
and B cells.
There is mounting evidence that prolonged placental P. fal-
ciparum infection, as reflected by high titers of anti-pregnancy-
associated malaria antibodies in cord blood, leads to greater
FIG. 3. IgM and IgG antibodies with specificity for DBL-3 pep-
tides are present in cord blood. A) The proportions of cord blood
samples containing IgM antibodies with specificity for DBL-3 pep-
tides, glutamate-rich protein (GLURP), or purified protein derivative
(PPD) in groups segregated by maternal P. falciparum infection history
during pregnancy. B) The proportions of cord plasma samples con-
taining IgM with specificity for at least one DBL-3 peptide. C) Dot
plot of DBL120 IgM antibody concentrations in plasma from malaria-
unexposed Europeans (positivity threshold: mean  3 standard devi-
ations, shown as a dotted line), Gabonese mothers’ peripheral blood
and cord blood segregated by maternal P. falciparum infection history
during pregnancy. D) Correlation between cord and maternal venous
blood IgG antibody levels for all DBL-3 peptides. Sample sizes:
negative, 25; placenta positive, 32; treated, 28; European controls, 12.
*, P  0.05 compared to negative group by Fisher exact test.
FIG. 4. A) IgG and B) IgM antibodies with specificity for the
DBL-3 peptides, glutamate-rich protein (GLURP), and purified pro-
tein derivative (PPD) in peripheral blood plasma from mothers at the
time of delivery. Samples are segregated by P. falciparum infection
history during pregnancy. Box-whisker plots show medians with 25th
and 75th and whiskers for 10th and 90th percentiles. Sample sizes:
negative, 25; placenta positive, 32; treated, 28; European controls, 12.
*, P  0.05 compared to negative group, Mann-Whitney test.
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susceptibility to malaria during infancy (6, 18). Untreated pla-
cental P. falciparum infection appears to further reduce al-
ready poor nonspecific neonatal T-cell responsiveness (13),
while our own work has shown that the presence of placental
P. falciparum infection at delivery is associated with reduced
major histocompatibility complex class I and II expression on
monocytes, and IL-10-mediated suppression of P. falciparum
antigen-specific Th1-type responses (2, 3). In the study pre-
sented here, cord blood samples of those born to mothers with
placental P. falciparum infection at delivery generally had the
highest anti-DBL-3 IgG antibody titers and the highest
DBL-3 peptide-specific IL-10 responses, findings that are
consistent with those of the studies cited above.
Although no statistically significant associations in cytokine
activity and P. falciparum infection during pregnancy were
found in mothers, peripheral blood mononuclear cells from
negative mothers contained elevated frequencies of DBL-3
peptide-specific CD3IL-13 cells. These results indicate that
increased frequencies of Th2-type cells (35), as well as Th1-
type 1 cells (20), are likely required for protection against P.
falciparum malaria in semi-immune adults. We did not see
significant enhancement of DBL-3 peptide-specific IgG or
IgM in plasma from negative mothers, although a trend toward
enhanced DBL78-specific IgG antibodies was observed. An
evaluation of IgG subtypes may reveal a different profile in-
dicative of protective antibodies in this group.
Although short peptides do not have conformations repre-
sentative of the native protein displayed on the surface of the
infected red blood cell, the controls that we used in this study
were intended to confirm sensitivity and to differentiate non-
specific responses. For example, the absence of strong antibody
responses to the DBL-3 peptides in nonexposed Europeans
validates an association of these response to our cohort, while
the parity dependency of maternal plasma antibody levels spe-
cific for peptides DBL78 and DBL120, but not glutamate-rich
protein, supports the idea that these two DBL-3 peptides are
specifically associated with pregnancy-associated malaria. Ad-
ditional studies are needed to determine the degree of speci-
ficity of the antibodies interacting with these DBL-3 peptides,
for example whether these antibodies are present in malaria
exposed adults who have not been pregnant, whether the ad-
dition of recombinant DBL-3 to the plasma prior to detection
of antibodies by ELISA reduces peptide-specific responses,
and whether the addition of the DBL-3 peptides would block
antibody binding to infected erythrocytes.
In summary, this study is the first to analyze maternal and
neonatal immune responses directed to peptides correspond-
ing to conserved regions of the DBL-3 domain of PfEMP1.
FIG. 5. Relationship between parity and maternal A) IgG and B) IgM antibody levels with specificity for DBL- peptides, glutamate-rich
protein (GLURP), or purified protein derivative (PPD). *, P  0.05. Spearman rank correlation.
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Two of the four peptides were particularly immunogenic, as-
sociated with both B- and T-cell responses in pregnant women
and their offspring. On the maternal side, higher levels of
antibodies recognizing one of these peptides were associated
with pregnancy-associated malaria and parity. On the fetal
side, the presence of both cytokine- and IgM peptide-specific
responses demonstrates that components of the DBL-3 do-
main of PfEMP1 cross the placental barrier and sensitize the
fetal immune system.
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